Lund, Sweden — 18 January 2019 — Camurus (NASDAQ STO: CAMX) today announced that that the Company will present at the SEB Biotech Seminar in Stockholm 24 January at 8:30 am. Fredrik Tiberg, President and CEO, will give an update on the company's activities, including the ongoing launch of Buvidal® weekly and monthly depots for the treatment of opioid dependence.
About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, VP Business Development
Tel. +46 (0)70 776 17 37
ir@camurus.com
This information was submitted for publication at 10.00 am CET on 18 January 2019.